WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Stock

$266.53+6.59 (+2.54%)
Updated Jun 5, 2023
MDGL Price
$266.53
Fair Value Price
$285.88
Market Cap
$4.87B
52 Week Low
$57.21
52 Week High
$322.67
P/E
-14.73x
P/B
32.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$314.73M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.21
Operating Cash Flow
-$259M
Beta
0.89
Next Earnings
Aug 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

MDGL Overview

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MDGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MDGL ($266.53) is undervalued by 6.77% relative to our estimate of its Fair Value price of $285.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MDGL ($266.53) is not significantly undervalued (6.77%) relative to our estimate of its Fair Value price of $285.88 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDGL due diligence checks available for Premium users.

Be the first to know about important MDGL news, forecast changes, insider trades & much more!

MDGL News

Valuation

MDGL fair value

Fair Value of MDGL stock based on Discounted Cash Flow (DCF)
Price
$266.53
Fair Value
$285.88
Undervalued by
6.77%
MDGL ($266.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDGL ($266.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MDGL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-14.73x
Industry
11.59x
Market
53.21x

MDGL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
32.47x
Industry
5.21x
MDGL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MDGL's financial health

Profit margin

Revenue
$0.0
Net Income
-$76.9M
Profit Margin
0%
MDGL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$332.4M
Liabilities
$182.3M
Debt to equity
1.21
MDGL's short-term assets ($331.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDGL's short-term assets ($331.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDGL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$84.1M
Investing
-$186.9M
Financing
$52.7M
MDGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MDGL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MDGL$4.87B+2.54%-14.73x32.47x
ALKS$4.89B-0.17%-29.46x4.87x
CRSP$4.98B-3.02%-9.39x2.68x
PCVX$4.77B+0.37%-14.76x5.05x
CERE$5.14B-1.74%-12.96x11.92x

Madrigal Pharmaceuticals Stock FAQ

What is Madrigal Pharmaceuticals's quote symbol?

(NASDAQ: MDGL) Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol MDGL. Madrigal Pharmaceuticals stock quotes can also be displayed as NASDAQ: MDGL.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

What is the 52 week high and low for Madrigal Pharmaceuticals (NASDAQ: MDGL)?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's 52-week high was $322.67, and its 52-week low was $57.21. It is currently -17.4% from its 52-week high and 365.88% from its 52-week low.

How much is Madrigal Pharmaceuticals stock worth today?

(NASDAQ: MDGL) Madrigal Pharmaceuticals currently has 18,289,173 outstanding shares. With Madrigal Pharmaceuticals stock trading at $266.53 per share, the total value of Madrigal Pharmaceuticals stock (market capitalization) is $4.87B.

Madrigal Pharmaceuticals stock was originally listed at a price of $318.15 in Feb 6, 2007. If you had invested in Madrigal Pharmaceuticals stock at $318.15, your return over the last 16 years would have been -16.23%, for an annualized return of -1.1% (not including any dividends or dividend reinvestments).

How much is Madrigal Pharmaceuticals's stock price per share?

(NASDAQ: MDGL) Madrigal Pharmaceuticals stock price per share is $266.53 today (as of Jun 5, 2023).

What is Madrigal Pharmaceuticals's Market Cap?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's market cap is $4.87B, as of Jun 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Madrigal Pharmaceuticals's market cap is calculated by multiplying MDGL's current stock price of $266.53 by MDGL's total outstanding shares of 18,289,173.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.